Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2018-01-01
2020-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The detection of MNV vascular details was only possible through invasive dye injection, such as fluorescein angiography (FA) or indocyanine green angiography (ICGA).
Optical coherence tomography angiography (OCTA) is a recent imaging technique that is able to detect the perfusion and non-perfusion areas carefully.
The aim of study is to compare the evaluation of dark halo area of MNV between ICGA and OCTA
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MNV group
Eyes affected by MNV. The dark halo of MNV was evaluated by OCTA and ICGA
Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)
OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)
OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of macular neovascularization
* absence of previous treatment with anti-Vegf injections
* absence of other retinal vascular diseases
Exclusion Criteria
* absence diagnosis of macular neovascularization
* presence of previous treatment with anti-Vegf injections
* presence of other retinal vascular diseases
55 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federico II University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gilda Cennamo
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilda Cennamo
Role: PRINCIPAL_INVESTIGATOR
Università Federico II
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Naples "Federico II"
Naples, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fossataro F, Cennamo G, Montorio D, Clemente L, Costagliola C. Dark halo, a new biomarker in macular neovascularization: comparison between OCT angiography and ICGA-a pilot prospective study. Graefes Arch Clin Exp Ophthalmol. 2022 Oct;260(10):3205-3211. doi: 10.1007/s00417-022-05693-8. Epub 2022 May 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9009/21
Identifier Type: -
Identifier Source: org_study_id